Mysimba is specifically formulated to help control hunger and cravings1,5

Mysimba combines — bupropion and naltrexone — in 1 tablet that targets two areas of the brain that cause hunger and cravings 1-3

A 3D image of a purple brain with a green circle highlighting the hypothalamus. The line on the left is connected to copy that reads <q>Mesolimbic Reward System</q> and the line on the right reads <q>Hypothalamus. </q>

Mysimba® targets 2 areas of the brain to give patients more control of their eating1,5*

*The exact neurochemical appetite suppressant effects of naltrexone/bupropion are not fully understood.5 Other areas of the brain may be involved.

View study results

References:

  1. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015;39(8):1188-1196.
  2. Reichelt AC, Westbrook RF, Morris MJ. Integration of reward signalling and appetite regulating peptide systems in the control of food-cue responses. Br J Pharmacol. 2015;172(22):5225-5238.
  3. Volkow ND, Wang GJ, Tomasi D, Baler RD. Obesity and addiction: neurobiological overlaps. Obes Rev. 2013;14(1):2-18.
  4. Pelchat ML. Of human bondage: food craving, obsession, compulsion, and addiction. Physiol Behav. 2002;76(3):347-352.
  5. Mysimba® SmPC available at https://www.medicines.org.uk/emc/product/2684/smpc#gref accessed September 2026
Reporting adverse effects: Adverse effects should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively you can report a suspected adverse drug reaction to the Yellow Card scheme by calling 0800 731 6789 Adverse events should also be reported to Orexigen®: +44 20 3966 0116 or currax.mi@primevigilance.com.
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014
Important Safety Information

Please refer to the Mysimba® Summary of Product Characteristics (SmPC)


▼ Black Triangle

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

MYS 014